Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study

Gut. 2022 Jun;71(6):1229-1231. doi: 10.1136/gutjnl-2021-325238. Epub 2021 Aug 2.

Gilaad G Kaplan^#¹, Christopher Ma^#², Carmen Charlton^{3

4

5}, Jamil N Kanji^{4

6

7}, Graham Tipples^{4

5

8}, Nastaran Sharifi², Michelle Herauf², Stephanie Coward², Richard J M Ingram², Lindsay Hracs², Eric I Benchimol⁹, Remo Panaccione²

¹ Division of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada ggkaplan@ucalgary.ca.
² Division of Gastroenterology & Hepatology, University of Calgary, Calgary, Alberta, Canada.
³ Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada.
⁴ Alberta Precision Laboratories, Public Health Laboratory, Edmonton, Alberta, Canada.
⁵ Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Alberta, Canada.
⁶ Department of Laboratory Medicine and Pathology, University of Calgary, Calgary, Alberta, Canada.
⁷ Division of Infectious Diseases, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
⁸ Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada.
⁹ Department of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.

^# Contributed equally.

No abstract available

Keywords: COVID-19; IBD.

Publication types